It is possible that patients in C6-KIRC/KIRP may respond to immunotherapeutics such as anti-PD1/PDL1 and anti-CTLA4 which are promising strategies in treatment of advanced melanoma and other tumor types [32–35]. Here, CD274 is linked to neoplasm.